Results 151 to 160 of about 4,942 (259)

Anticorpi monoclonali e inclisiran: alla ricerca del paziente ideale [PDF]

Andrea Rubboli, Claudio Cuccia
openalex   +1 more source

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran [PDF]

, 2022
Ahmed Shawky, Ahmed Bendary, Atef Elbahry, Elsayed Farag, Tamer Mostafa, Osama Sanad, Ahmed Elkersh, Mohammed Selim, Hany Ragy, Hazem Khamis, Waleed Abdo, Ashraf Reda   +11 more
openalex   +1 more source

New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO) [PDF]

, 2022
Hana Rosolová
openalex   +1 more source

Inclisiran - a new representative of dyslipidemia biological treatment [PDF]

, 2023
David Karásek
openalex   +1 more source

(Inclisiran - the first experiences)

Cor et Vasa, 2023
Michaela Štroffeková, Jana Obrová, Miloš Táborský   +2 more
openaire   +1 more source

New prospects in treatment of dyslipidaemia – putting patient compliance first [PDF]

, 2022
Merćep, Iveta, Slišković, Ana Marija, Sopek-Merkaš, Ivana, Strikić, Dominik, Vujević, Andro   +4 more
core   +2 more sources

Correction to: Inclisiran: First Approval [PDF]

Drugs, 2021
openaire   +1 more source

Insights from ORION studies: focus on inclisiran safety [PDF]

Cardiovascular Research, 2020
Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata   +2 more
openaire   +2 more sources

EE157 The Societal Impact of Inclisiran Using Population Health Approaches Across 15 Countries [PDF]

, 2023
Dennis A. Ostwald, Martín Müller, Mélanie Schmitt, Platon Peristeris, Adnan Atitallah, Lena Steinbeck, Johannes Müller, Katharina Buesch   +7 more
openalex   +1 more source

Research Progress of Inclisiran

Advances in Clinical Medicine, 2022
openaire   +1 more source